This page shows the latest epoetin alfa news and features for those working in and with pharma, biotech and healthcare.
COMMAND is a phase 3, open-label, randomised trial evaluating the efficacy and safety of Reblozyl versus epoetin alfa.
According to analysis included in the FDA briefing documents, roxadustat was comparable to epoetin alfa, a standard therapy for anaemia in CKD, on the composite measure of major adverse cardiovascular events ... MACE). However, the FDA raised concerns
According to this analysis, roxadustat was comparable to epoetin alfa, a standard therapy for anaemia in CKD, on the composite measure of major adverse cardiovascular events (MACE). ... events. The risk is thought to be most acute with epoetin alfa when
If approved, daprodustat would be an oral alternative to erythropoiesis-stimulating agents (ESAs) such as Kyowa Kirin’s Espo (epoetin alfa) and biosimilars that have to be delivered by injection.
events. The risk is thought to be most acute with epoetin alfa when treatment is started, typically in patients in newly-initiated (incident) dialysis. ... Epoetin alfa is sold by Amgen as Epogen and Janssen as Procrit, but these brands were joined by
The ROCKIES trial revealed a significant improvement for the oral drug in haemoglobin versus injectable epoetin alfa in dialysis-dependent CKD patients, the patient population for which it has just been
More from news
Approximately 1 fully matching, plus 40 partially matching documents found.
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...